This is a new drug which has shown promise in animal studies, but has never before been used to treat ALS in humans. We were one of 10 centers who participated in a placebo-controlled phase IIa study of this drug, which demonstrated excellent safety and tolerability. A larger study to assess efficacy is planned for 2008.
Contact information: Helen (Beth) Stephens, 717-531-0003, ext 283395 or hstephens1@hmc.psu.edu
Ceftriaxone in ALS
Ceftriaxone is an antibiotic which can remove glutamate from the nervous system. Because glutamate is believed to be a cause of motor neuron damage and death in ALS, such an approach should benefit individuals with ALS. A multi-center clinical trial of ceftriaxone in ALS is planned for 2008.
Contact information: Helen (Beth) Stephens, 717-531-0003, ext 283395 or hstephens1@hmc.psu.edu
